ClinicalTrials.gg
CompletedNCT03890770Updated Mar 12, 2021

A Study to Assess the Safety of Experimental Medication BMS986165 in Participants With Normal Kidney Function and Participants With Mild to End-Stage Kidney Disease.

A Phase 1 interventional study of BMS-986165 in Renal Impairment and Healthy Volunteer, sponsored by Bristol-Myers Squibb. Completed at 6 sites in 4 countries. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-03-12.

Sponsored by Bristol-Myers Squibb · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Feb 2020, 6 years 9 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
44
Allocation
Non-randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies in Renal Insufficiency by Bristol-Myers Squibb — none open to participants now, none under way, none of them phase 3. Renal Insufficiency · Bristol-Myers Squibb.

Enrollment
4th of 12
44 · median 31
Started
2019
the only one that year
Phase 1
11 of 15
none open now
Registered
11th of 15
by date

Among the 15 studies in Renal Insufficiency by Bristol-Myers Squibb, this one is the 4th largest by enrollment of the 12 interventional ones that give a count, is the only one that started in 2019, is one of 11 in phase 1, and was the 11th registered.

Renal Insufficiency

1,413 studies on the registry are indexed under Renal Insufficiency; 146 are open to participants now.

Browse Renal Insufficiency studies →

Open to participants now

None of the 15 studies in Renal Insufficiency by Bristol-Myers Squibb is open now. The open studies under Renal Insufficiency, anywhere →

Who these studies take

Of the 92 Renal Insufficiency studies recruiting now, 48 (52%) set no upper age limit and 19 (21%) stop at 75 or younger; 8 take children under 18; 15 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 15 studies in Renal Insufficiency by Bristol-Myers Squibb as a file.
02

Study summary

The purpose of this study is to investigate BMS-986165 in participants with different levels of kidney function.

03

Conditions studied

  • Renal Impairment
  • Healthy Volunteer

Browse trials for

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com

Inclusion criteria

Inclusion Criteria:

  • Participants must be judged to be in good health in the opinion of the investigator OR participant has a stable disease (eg, hypertension, hyperlipidemia, diabetes mellitus, hyperthyreosis) under medical control (ie, no changes in medication within 30 days prior to study drug administration)
  • Stable renal impairment, defined as no change in disease status, as documented by the participant's most recent assessment; eGFR must not vary more than 30% from screening to Day -1 to confirm stable renal function, and the renal impairment must be expected by the investigator not to change significantly during the next 3 months
  • of 18.0 to 38.0 kg/m2, inclusive, and weight ≥50 kg, at screening

Exclusion criteria

Exclusion Criteria:

  • abnormal medical history, abnormal findings on physical examination, vital signs, , or laboratory tests at screening that the investigator judges as likely to interfere with the objectives of the trial or the safety of the participant
  • Have a history of cancer () with the following exceptions: (1) subjects with adequately treated non-melanomatous skin carcinoma or carcinoma in situ of the cervix may participate in the trial; (2) subjects with other malignancies that have been successfully treated ≥10 years prior to the screening visit where, in the judgment of both the investigator and treating physician, appropriate follow-up has revealed no evidence of recurrence from the time of treatment through the time of the screening visit
  • History or clinical evidence of acute or chronic bacterial infection (eg, pneumonia, septicemia) within 3 months prior to screening

Other protocol defined inclusion/exclusion criteria could apply

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
44 participants (actual)

Study arms

  • Experimental
    Normal renal function

    Single dose

    Drug: BMS-986165

  • Experimental
    Mild renal disease

    Single dose

    Drug: BMS-986165

  • Experimental
    Moderate renal failure

    Single dose

    Drug: BMS-986165

  • Experimental
    Severe renal failure

    Single dose

    Drug: BMS-986165

  • Experimental
    End-stage renal disease requiring dialysis

    Two single doses administered with washout

    Drug: BMS-986165

Interventions

06

What researchers measure

Primary outcomes

  1. Maximum observed plasma concentration (Cmax)

    Time frame: Approximately 9 days

  2. Area under the plasma concentration-time curve from time zero to the time of the last quantifiable concentration [AUC(0-T)]

    Time frame: Approximately 9 days

  3. Area under the plasma concentration-time curve from time zero extrapolated to infinite time [AUC(INF)]

    Time frame: Approximately 9 days

Secondary outcomes

  1. Incidence of nonserious adverse events (AE), serious adverse events (SAE), and AE leading to discontinuation

    Time frame: Approximately 45 days

  2. Number of clinically significant changes in clinical laboratory values, vital signs, ECGs, and physical examinations

    Time frame: Approximately 45 days

07

Study locations

6 sites
  • Orlando Clinical Research Center
    Orlando, Florida 32809, United States
  • Pharmaceutical Research Associates CZ, s.r.o
    Praha 7, 170 00, Czechia
  • Szent Imre Egyetemi Oktatokorhaz
    Budapest, 1115, Hungary
  • Kenezy Gyula Korhaz es Rendelointezet
    Debrecen, 4043, Hungary
  • Samodzielny Publiczny Secjalistyczny Szpital Zachodni im. sw. Jana Pawla II
    Grodzisk Mazowiecki, 05-825, Poland
  • Specjalistyczne Centrum Medyczne Chirurgii Maloinwazyjnej SCM
    Krakow, 31-559, Poland
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2019 to primary completion in Feb 2020, 10 months.

Of 213 industry-sponsored phase 1 interventional studies under Renal Insufficiency, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's 10 months is above that.

Counting every sponsor, half of 231 studies reached it within 8 months; a quarter within 5 and three quarters within 16.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 25, 2019
First posted
Mar 26, 2019
StartActual
Apr 4, 2019
Primary completionActual
Feb 7, 2020
CompletionActual
Feb 13, 2020
Last update
Mar 12, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 12, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03890770
Responsible party
Sponsor
First posted
Mar 26, 2019
Start date
Apr 4, 2019
Primary completion
Feb 7, 2020
Completion
Feb 13, 2020
Last update
Mar 12, 2021

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Deucravacitinib

Start the discussion